Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sirnaomics Ltd. ( (HK:2257) ) has shared an update.
Sirnaomics Ltd. announced the partial completion of a subscription agreement, resulting in the issuance of 1,003,700 new shares to Subscriber B at HK$12.00 per share. The termination of the remaining shares in the agreement was mutually agreed upon, with no adverse impact on the company’s operations or financial conditions. The net proceeds of approximately HK$12.0 million will be used for the development and commercialization of their drug candidates, enhancing the company’s strategic focus on advancing its RNAi therapeutics portfolio.
The most recent analyst rating on (HK:2257) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.
More about Sirnaomics Ltd.
Sirnaomics Ltd. operates in the biotechnology industry, focusing on the development and commercialization of RNAi therapeutics. The company is engaged in advancing its primary products, including STP705, STP122G, and other drug candidates like STP707 and STP125G.
Average Trading Volume: 799,489
Technical Sentiment Signal: Sell
Current Market Cap: HK$736.1M
See more insights into 2257 stock on TipRanks’ Stock Analysis page.